Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours

British Journal of Cancer

Volumn 117, Issue 7, 2017, Pages 1017-1025

  Sefrioui, David ^a,b   Blanchard, France ^a   Toure, Emmanuel ^a   Basile, Paul ^a   Beaussire, Ludivine ^b   Dolfus, Claire ^a   Perdrix, Anne ^b,c   Paresy, Marianne ^a   Antonietti, Michel ^a   Iwanicki Caron, Isabelle ^a   Alhameedi, Raied ^a   Lecleire, Stephane ^a   Gangloff, Alice ^a   Schwarz, Lilian ^a   Clatot, Florian ^b,c   Tuech, Jean Jacques ^a   Frébourg, Thierry ^a,b   Jardin, Fabrice ^b,c   Sabourin, Jean Christophe ^a,b   Sarafan Vasseur, Nasrin ^b   Michel, Pierre ^a,b   Di Fiore, Frédéric ^a,b,c   more..

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c CENTRE HENRI BECQUEREL   (France)

Author keywords

CA19.9; circulating tumour cells; circulating tumour DNA; endoscopic ultrasound guided fine needle aspiration; pancreatic adenocarcinoma; solid pancreatic tumours

Indexed keywords

CA 19-9 ANTIGEN; CIRCULATING TUMOUR DNA; DNA; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN NEOPLASM; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEMALE; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA WITH PANCREAS INVASION; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ISLET CELL TUMOR; PANCREAS TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; RENAL CELL CARCINOMA; SENSITIVITY AND SPECIFICITY; SOLID MALIGNANT NEOPLASM; SOLID PSEUDOPAPILLARY TUMOR; TASK PERFORMANCE; ADENOCARCINOMA; ADOLESCENT; BLOOD; FOLLOW UP; GENETICS; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL RATE; TUMOR EMBOLISM; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; DNA, NEOPLASM; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE; YOUNG ADULT;

EID: 85029898885     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.250     Document Type: Article

References (46)

1. ASGE Standards of Practice Committee Eloubeidi MA, Decker GA, Chandrasekhara V, Chathadi KV, Early DS, Evans JA, Fanelli RD, Fisher DA, Foley K, Hwang JH, Jue TL, Lightdale JR, Pasha SF, Saltzman JR, Sharaf R, Shergill AK, Cash BD, DeWitt JM (2016) The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointest Endosc 83: 17-28.
2. Azuara D, Ginesta MM, Gausachs M, Rodriguez-Moranta F, Fabregat J, Busquets J, Pelaez N, Boadas J, Galter S, Moreno V, Costa J, de Oca J, Capellá G (2012) Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. Clin Chem 58: 1332-1341.
3. Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3: 105-119.
4. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong S-M, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SKN, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih LE-M, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang T-L, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz Jr LA (2014) Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 6: 224ra24.
5. Beutler E, Gelbart T, Kuhl W (1990) Interference of heparin with the polymerase chain reaction. BioTechniques 9: 166.
6. Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P (2013) Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol 24: 2057-2061.
7. Brychta N, Krahn T, von Ahsen O (2016) Detection of KRAS mutations in circulating tumor DNA by Digital PCR in early stages of pancreatic cancer. Clin Chem 62: 1482-1491.
8. Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, Blasutig IM (2014) Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res 20: 5787-5795.
9. DeWitt J, Jowell P, Leblanc J, McHenry L, McGreevy K, Cramer H, Volmar K, Sherman S, Gress F (2005) EUS-guided FNA of pancreatic metastases: a multicenter experience. Gastrointest Endosc 61: 689-696.
10. Diaz Jr LA, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32: 579-586.
11. Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodŕiguez-Garrote M, Lisa E, Mendia E, Lobo E, Malats N, Carrato A, Guillen-Ponce C (2015) Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer 15: 797.
12. Eloubeidi MA, Chen VK, Eltoum IA, Jhala D, Chhieng DC, Jhala N, Vickers SM, Wilcox CM (2003a) Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am J Gastroenterol 98: 2663-2668.
13. Eloubeidi MA, Jhala D, Chhieng DC, Chen VK, Eltoum I, Vickers S, Mel Wilcox C, Jhala N (2003b) Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer 99: 285-292.
14. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, Stefancsik R, Harsha B, Kok CY, Jia M, Jubb H, Sondka Z, Thompson S, De T, Campbell PJ (2017) COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 45: D777-D783.
15. Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE (2014) Circulating tumor cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol 25: 1506-1516.
16. Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, Sueda T, Hiyama E (2016) Prognostic value of circulating tumor DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer 115: 59-65.
17. Harewood GC, Wiersema MJ (2002) Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am J Gastroenterol 97: 1386-1391.
18. Hofman V, Long E, Ilie M, Bonnetaud C, Vignaud JM, Fléjou JF, Lantuejoul S, Piaton E, Mourad N, Butori C, Selva E, Marquette CH, Poudenx M, Sibon S, Kelhef S, Vénissac N, Jais JP, Mouroux J, Molina TJ, Vielh P, Hofman P (2012) Morphological analysis of circulating tumor cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumor cell (ISET) method. Cytopathology 23: 30-38.
19. Iwanicki-Caron I, Basile P, Toure E, Antonietti M, Lecleire S, Di Fiore A, Oden-Gangloff A, Blanchard F, Lemoine F, Di Fiore F, Sabourin JC, Michel P (2013) Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis. Am J Gastroenterol 108: 152-155.
20. Jackson JB, Choi DS, Luketich JD, Pennathur A, Ståhlberg A, Godfrey TE (2016) Multiplex preamplification of serum DNA to facilitate reliable detection of extremely rare cancer mutations in circulating DNA by digital PCR. J Mol Diagn 18: 235-243.
21. Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388: 73-85.
22. Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle JW, Dive C (2012) A pilot study to explore circulating tumor cells in pancreatic cancer as a novel biomarker. Br J Cancer 106: 508-516.
23. Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, Tsutsumi K, Kato H, Matsubara T, Okada H, Yamamoto K (2015) Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer 121: 2271-2280.
24. Kulemann B, Pitman MB, Liss AS, Valsangkar N, Fernández-Del Castillo C, Lillemoe KD, Hoeppner J, Mino-Kenudson M, Warshaw AL, Thayer SP (2015) Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas 44: 547-550.
25. Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, Ishii K, Ikeuchi N, Tsuchida A, Kasuya K, Kawai T, Sakai Y, Moriyasu F (2008) Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg 15: 189-195.
26. Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin J-C (2011) Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 24: 1090-1100.
27. LeBlanc JK, Ciaccia D, Al-Assi MT, McGrath K, Imperiale T, Tao L-C, Vallery S, DeWitt J, Sherman S, Collins E (2004) Optimal number of EUS-guided fine needle passes needed to obtain a correct diagnosis. Gastrointest Endosc 59: 475-481.
28. Nouts A, Lévy P, Voitot H, Bernades P (1998) Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterol Clin Biol 22: 152-159.
29. Poruk KE, Valero V, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL (2016) Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma. Ann Surg 264: 1073-1081.
30. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE (2015) Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 6: 7686.
31. Sefrioui D, Perdrix A, Sarafan-Vasseur N, Dolfus C, Dujon A, Picquenot J-M, Delacour J, Cornic M, Bohers E, Leheurteur M, Rigal O, Tennevet I, Thery J-C, Alexandru C, Guillemet C, Moldovan C, Veyret C, Frebourg T, Di Fiore F, Clatot F (2015a) Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer 137: 2513-2519.
32. Sefrioui D, Sarafan-Vasseur N, Beaussire L, Baretti M, Gangloff A, Blanchard F, Clatot F, Sabourin J-C, Sesboüé R, Frebourg T, Michel P, Di Fiore F (2015b) Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Dig Liver Dis 47: 884-890.
33. Singh N, Gupta S, Pandey RM, Chauhan SS, Saraya A (2015) High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival. Cancer Invest 33: 78-85.
34. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R (2000) Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 89: 83-88.
35. Steinberg W (1990) The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85: 350-355.
36. Su S-B, Qin S-Y, Chen W, Luo W, Jiang H-X (2015) Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 21: 4323-4333.
37. Sweeney AD, Wu M-F, Hilsenbeck SG, Brunicardi FC, Fisher WE (2009) Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res 156: 189-198.
38. Tadic M, Kujundzic M, Stoos-Veic T, Kaic G, Vukelic-Markovic M (2008) Role of repeated endoscopic ultrasound-guided fine needle aspiration in small solid pancreatic masses with previous indeterminate and negative cytological findings. Dig Dis 26: 377-382.
39. Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N, Suzuki M, Furukawa E, Kato M, Hayashi H, Kohno T, Ueno H, Shimada K, Okusaka T, Nakagama H, Shibata T, Yachida S (2015) Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep 5: 18425.
40. Uehara H, Ikezawa K, Kawada N, Fukutake N, Katayama K, Takakura R, Takano Y, Ishikawa O, Takenaka A (2011) Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration for suspected pancreatic malignancy in relation to the size of lesions. J Gastroenterol Hepatol 26: 1256-1261.
41. Varadarajulu S, Tamhane A, Eloubeidi MA (2005) Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. Gastrointest Endosc 62: 728-736.
42. Visani M, de Biase D, Baccarini P, Fabbri C, Polifemo AM, Zanini N, Pession A, Tallini G (2013) Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells. Int J Surg Pathol 21: 546-552.
43. Wang P, Bahreini A, Gyanchandani R, Lucas P, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss K, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla S, Lee AW, Oesterreich S (2015) Sensitive detection of mono-and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients. Clin Cancer Res 22: 1130-1137.
44. Winter JM, Yeo CJ, Brody JR (2013) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107: 15-22.
45. Yoshinaga S, Suzuki H, Oda I, Saito Y (2011) Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses. Dig Endosc 23(Suppl 1): S29-S33.
46. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA (2015) Cell-Free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov 5: 1040-1048.